{"title":"治疗精神分裂症的革命性药物获得美国批准","authors":"Elie Dolgin","doi":"10.1038/d41586-024-03123-9","DOIUrl":null,"url":null,"abstract":"The medication is the first in decades to have a different mode of action from those of current drugs, achieving better symptom relief with fewer side effects. The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.","PeriodicalId":18787,"journal":{"name":"Nature","volume":"634 8033","pages":"276-277"},"PeriodicalIF":48.5000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/d41586-024-03123-9.pdf","citationCount":"0","resultStr":"{\"title\":\"Revolutionary drug for schizophrenia wins US approval\",\"authors\":\"Elie Dolgin\",\"doi\":\"10.1038/d41586-024-03123-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The medication is the first in decades to have a different mode of action from those of current drugs, achieving better symptom relief with fewer side effects. The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.\",\"PeriodicalId\":18787,\"journal\":{\"name\":\"Nature\",\"volume\":\"634 8033\",\"pages\":\"276-277\"},\"PeriodicalIF\":48.5000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.nature.com/articles/d41586-024-03123-9.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://www.nature.com/articles/d41586-024-03123-9\",\"RegionNum\":1,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature","FirstCategoryId":"103","ListUrlMain":"https://www.nature.com/articles/d41586-024-03123-9","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Revolutionary drug for schizophrenia wins US approval
The medication is the first in decades to have a different mode of action from those of current drugs, achieving better symptom relief with fewer side effects. The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.
期刊介绍：
Nature is a prestigious international journal that publishes peer-reviewed research in various scientific and technological fields. The selection of articles is based on criteria such as originality, importance, interdisciplinary relevance, timeliness, accessibility, elegance, and surprising conclusions. In addition to showcasing significant scientific advances, Nature delivers rapid, authoritative, insightful news, and interpretation of current and upcoming trends impacting science, scientists, and the broader public. The journal serves a dual purpose: firstly, to promptly share noteworthy scientific advances and foster discussions among scientists, and secondly, to ensure the swift dissemination of scientific results globally, emphasizing their significance for knowledge, culture, and daily life.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
